Poly MedicureNSE:POLYMED +0.15%90 EBITDA Margin % is 24.30% as of Mar. 2026, which is 12% below its 10-year median of 27.56. GuruFocus rates NSE:POLYMED with a GF Score™ of 90/100 and a GF Value™ of ₹2,289.81 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Poly Medicure ranks better than 90.44% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Poly Medicure's EBITDA for the
three
months ended in Mar. 2026 was ₹1,299 Mil. Poly Medicure's Revenue for the
three
months ended in Mar. 2026 was ₹5,345 Mil. Therefore, Poly Medicure's EBITDA margin for the quarter that ended in Mar. 2026 was 24.30%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Poly Medicure EBITDA Margin % Related Terms
Poly Medicure EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Poly Medicure's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:POLYMED vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Poly Medicure's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poly Medicure EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Poly Medicure's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Poly Medicure's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poly Medicure (NSE:POLYMED) has a EBITDA Margin % of 24.30% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Poly Medicure and its competitors. This is 12% below median its historical median of 27.56. Over the past decade, Poly Medicure's EBITDA Margin % has ranged from 23.63 to 32.80. According to the industry distribution chart, Poly Medicure ranks #78 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 9.6%.
Is Poly Medicure's EBITDA Margin % too high?
Poly Medicure's current EBITDA Margin % of 24.30% is 12% below median its 10-year median of 27.56. Over the past 10 years, this metric has ranged from a low of 23.63 to a high of 32.80. The Medical Devices & Instruments industry median EBITDA Margin % is 7.39. Poly Medicure's value of 24.30% is 229% above this industry median. Based on the distribution chart, Poly Medicure ranks #78 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Poly Medicure has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Poly Medicure's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Poly Medicure ranks #78 out of 816 companies for EBITDA Margin %. This places Poly Medicure in the top 10% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.39. Poly Medicure's value of 24.30% is 229% above this benchmark. Historically, Poly Medicure's own EBITDA Margin % has ranged from 23.63 to 32.80 over the past decade. While the company's 10-year median is 27.56 vs. the industry median of 7.39, Poly Medicure has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.39, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Poly Medicure's current EBITDA Margin % of 24.30% is 229% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Poly Medicure and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poly Medicure's current EBITDA Margin % is 24.30%, which is 12% below median its own 10-year median of 27.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poly Medicure stock overvalued right now?
Based on GuruFocus' analysis, Poly Medicure (NSE:POLYMED) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,289.81, compared to a current price of ₹1,652.60 — trading 27.8% below its estimated fair value. The current EBITDA Margin % is 24.30%, which is 12% below median its 10-year median of 27.56 and 229% above the Medical Devices & Instruments industry median of 7.39. Poly Medicure's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Poly Medicure (NSE:POLYMED), the current EBITDA Margin % is 24.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Poly Medicure (NSE:POLYMED) Overvalued in 2026?
Based on GuruFocus' analysis, Poly Medicure stock appears to be undervalued.
The current stock price of ₹1,652.60 is trading 27.8% below its estimated GF Value™ of ₹2,289.81.
GuruFocus considers Poly Medicure to be Modestly Undervalued.
Key valuation signals for NSE:POLYMED:
EBITDA Margin %: 24.30% (12% below median its 10-year median of 27.56)
GF Value™: ₹2,289.81 vs. price of ₹1,652.60 (27.8% below fair value)
Industry Position: 229% above the Medical Devices & Instruments median (#78 of 816)
No single metric tells the full story. See the NSE:POLYMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Poly Medicure Ltd engages in the manufacturing and sale of medical devices. It offers disposable medical devices for infusion therapy, blood management, gastroenterology, vascular access, surgery and wound drainage, anesthesia, and urology. Some of its products include Ventilator Circuit Combo Kits, Bain Circuits, Safety Introducer Needles, High-Pressure Vaccum Bottle-Triplet, Catheters, and others. Geographically, it derives a majority of its revenue from exports. The company operates under one segment namely Medical Devices.
90GF Score
Get the complete analysis for NSE:POLYMED
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:POLYMED has been successfully added to your 
